This study assessed the safety and efficacy of filgrastim (r-metHuG-CSF [recombinant human methionine granulocyte colony-stimulating factor]), when combined with intravenous (IV) antibiotics, in the treatment of hospitalized adult patients with multilobar communityacquired pneumonia (CAP). Four hundred eighty patients were randomized to receive placebo ( ) or filgrastim 300 mg/day ( ), in addition to standard therapy. Treatment with n p 243 n p 237 study drug was continued for 10 days, until the peak white blood cell (WBC) count reached /L, until discharge from the hospital, until death, or until IV antibiotics were discon- 13.3 ϫ 10 43.8 ϫ 10 were not statistically different with respect to the study end points; however, there was a trend toward reduction of mortality in patients with pneumococcal bacteremia. Although further studies will be required to validate this observation, filgrastim was safe and well tolerated when administered to patients with multilobar CAP.
ϫ 10
43.8 ϫ 10 were not statistically different with respect to the study end points; however, there was a trend toward reduction of mortality in patients with pneumococcal bacteremia. Although further studies will be required to validate this observation, filgrastim was safe and well tolerated when administered to patients with multilobar CAP.
Data from a randomized, placebo-controlled, phase 3 study in patients with community-acquired pneumonia (CAP) suggested that filgrastim (r-metHuG-CSF [recombinant human methionine granulocyte colony-stimulating factor]), in combination with intravenous (IV) antibiotics, hastened the resolution of pneumonia [1] . In this study, resolution of pneumonia was based on a composite outcome measurement, time to resolution of morbidity (TRM), which included temperature, respiratory rate, blood oxygenation, and chest radiograph [2] . Other outcome measurements were 28-day mortality, length of Each subject or legal guardian gave his or her written informed consent to participate in the study. The study was conducted in accordance with Food and Drug Administration regulations. The current version of the Declaration of Helsinki on experimentation in humans was observed in all respects. The institutional review board of each institution approved the protocol and informed consents. stay in hospital, and adverse events. Although TRM, mortality, and length of stay were not altered by the addition of filgrastim, filgrastim did accelerate radiographic improvement, increased neutrophil counts 3-fold, and appeared to reduce serious complications in patients with CAP.
In a 5-year longitudinal study, Marrie et al. [3] identified multilobar pneumonia as a predictor of poor prognosis. Multilobar infiltrates are included in guidelines written by the American Thoracic Society as a condition for meeting the definition of severe pneumonia [4] . A post hoc analysis of a subset of patients with multilobar pneumonia in the study by Nelson et al. [1] suggested that patients who received filgrastim had better clinical outcome than did patients who did not. We hypothesized that the 28-day failure rate would be decreased in patients treated with filgrastim, compared with patients administered placebo.
Patients and Methods
Study design. This was a multicenter, randomized, placebocontrolled, double-blind trial. Eligible patients were randomized to receive filgrastim or placebo, in addition to standard therapy to treat multilobar pneumonia. Study drug was started within 24 h of hospitalization and was continued for р10 days or until the peak white blood cell (WBC) count reached , IV an- 9 1 75 ϫ 10 /L tibiotics were discontinued, or the patient was discharged from the hospital.
Study-related observations, including vital signs, laboratory determinations, adverse events, chest radiographs, onset of organ dysfunction, empyema, and mortality, continued through day 29.
Patients. Hospitalized patients who were у18 years old and were receiving IV antibiotics for multilobar pneumonia were eligible for enrollment if they met other specific requirements, including bacteriological confirmation of pneumonia by either positive sputum Gram's stain with у25 WBCs and р10 squamous epithelial cells per low-power field, or bacteremia; hypoxia (PaO 2 / FiO 2 !285 or oxygen saturation !88% for 5 consecutive min); tachypnea (respiratory rate 124); fever (temperature у38.0ЊC); unexplained hypothermia (temperature р36ЊC); leukocytosis (WBC у /L); or relative leukopenia (WBC р /L). Potential 9 9 12 ϫ 10 4 ϫ 10 subjects were expected to require у72 h of IV antibiotic therapy and to agree to allow full respiratory and cardiovascular support.
Patients who were pregnant or breast feeding were excluded, as were patients who had AIDS, acute respiratory distress syndrome (ARDS), acute renal failure (ARF), shock, disseminated intravascular coagulation (DIC), empyema, unstable angina, New York Heart Association class IV congestive heart failure, myocardial infarction within 30 days of study enrollment, or significant hematological abnormalities. Patients could not have known sensitivities to Escherichia coli-derived products, be receiving dialysis, have had treatment with cytotoxic chemotherapy, radiotherapy, or investigational drugs within 1 month of study enrollment, or have had a parenteral antibiotic or ventilator support for 24 h before randomization.
Treatment. Filgrastim (300 mg/day) or placebo (vehicle in identical vial, both from Amgen, Inc., Thousand Oaks, CA) was given as a subcutaneous injection within 4 h of randomization and was continued for р10 days. Study drug administration was discontinued if WBC count was 1 /L 19-24 h after study drug ad-9 75 ϫ 10 ministration, when IV antibiotics were discontinued, in the event of a serious adverse event, or on patient's discharge or request. The medical staff at each study center directed antibiotic therapy choice and management according to institutional policy.
Supportive care and monitoring. Full supportive care, including transfusion of blood or blood products, as well as administration of concomitant medicines, was allowed as medically indicated.
Vital signs were recorded daily, and a chest radiograph was repeated at least every other day until day 29, discharge, or resolution. Microbiologic cultures were obtained as clinically indicated, and patients with a positive baseline blood culture were followed until the culture was negative. WBC counts with differential and platelet counts were done daily through day 10 or until the day of discharge, if earlier. Serum chemistry tests were repeated on days 5 and 10, if the patient remained hospitalized. Patients were assessed daily for the development of organ dysfunction or empyema through day 29.
Study end points and sample size. The primary efficacy end point was the incidence of therapeutic failure through day 29. Therapeutic failure was defined as development of organ dysfunction (ARDS, DIC, ARF, or shock), empyema, or death from any cause. Secondary efficacy end points included 28-day mortality, number of days in the intensive care unit, time to stability or improvement as demonstrated by chest radiograph, and incidence of chest radiograph resolution. Safety end points were adverse events and clinical laboratory abnormalities.
The sample size was estimated by assuming that the 28-day failure rate would be 22.8% among patients in the placebo group and that filgrastim therapy would result in an absolute decrease in the proportion of treatment failures by ∼50%.
Statistical methods. The proportion of patients experiencing therapeutic failure was compared using the Cochran-MantelHaenszel (CMH) test. Kaplan-Meier estimates for time-to-event end points were compared using log-rank statistics. Adverse events were tabulated by organ system, severity, and relationship to study drug. The primary analysis was based on an intent-to-treat paradigm. Secondary analyses were based on an evaluable subset of subjects who met all eligibility requirements and received у3 doses of study drug.
Results

Patients.
Between September 1996 and February 1999, 480 patients were enrolled in 105 hospital centers throughout Australia, Canada, and the United States. Two hundred thirtyseven patients received filgrastim, and 243 received placebo. Sixteen patients (3%) did not complete the study. The reasons for early termination included patient request (placebo, 5; filgrastim, 4), administrative decision (3 each group), and loss to follow-up (placebo, 1). There were 27 deaths in the placebo group, and 19 in the filgrastim group.
The 2 groups were balanced in terms of age, sex, race, baseline disease characteristics, and baseline vital signs and blood gases (table 1) .
Overall, 213 placebo-treated patients (94%) and 203 (92%) filgrastim-treated patients had a causative pathogen identified in the baseline sputum sample. The frequencies of most common (15%) pathogens isolated from blood or sputum samples at baseline are given in table 1 .
Drug administration and responses. Patients received a median of 5 doses of filgrastim. Median peak WBC counts (i.e., the median of the highest individual patient values) were /L among placebo patients and /L among 9 9 16.5 ϫ 10 43.8 ϫ 10 filgrastim-treated patients. The median time for filgrastimtreated patients to reach peak WBC count was 5 days.
Efficacy end points. The incidence of patients experiencing therapeutic failure (i.e., ARDS, ARF, DIC, shock, empyema, or death) through day 29 was 42 (17.3%) in the placebo group and 40 (16.9%) in the filgrastim group (table 2). The difference between the 2 groups was not statistically significant (CMH ; ), on the basis of an intent-to-treat anal-2 x ! 0.0001 P p .984 ysis or evaluable subset analyses. The underlying causes of death were similar in both groups, with pneumonia/sepsis, pneumonia, cardiac failure, and chronic obstructive pulmonary disease (COPD) being the most frequent (range 1%-4%).
No statistically significant effect of treatment group was observed on any of the secondary end points. The incidence of mortality through day 29 was 28 (11.6%) in the placebo group and 19 (8.0%) in the filgrastim-treated group (CMH 2 x p ; ) . 1.804 P p .179 One hundred sixty-two (33.7%) patients entered an intensive care unit (ICU) during the study. The median time spent in an ICU while on study was 6 days for both the placebo and filgrastim-treated groups ( ). P p .462 The median time to stability or improvement of infiltrates on chest radiographs was 2 days for both groups (log-rank test, ), and the incidence of resolution of infiltrate on chest P p .124 radiograph through day 29 was 45 (19.1%) for the placebo group and 53 (22.8%) for the filgrastim-treated group (CMH ; ) .
Similar bacterial culture isolation rates were observed in sputum and blood cultures from the placebo and filgrastim groups (table 1) ; however, patients who had a positive blood culture for Streptococcus pneumoniae and who received filgrastim showed a decreased mortality, compared with the placebo group (22% for placebo vs. 6.5% for filgrastim;
). No differ-P ! .070 ences in general antibiotic use (macrolides, quinolones, cephalosporins) with filgrastim and mortality outcome were seen.
Safety end points. Among evaluable patients, 1141 adverse events were reported among 201 (84%) placebo patients, and 1162 events were reported among 204 (87%) filgrastim-treated patients. Adverse events were similar in type and frequency for both treatment groups. The most frequent adverse events reported with a difference in frequency у2% between the 2 treatment groups were ARDS (placebo, 7%; filgrastim, 10%), respiratory insufficiency (placebo, 4%; filgrastim, 2%), cardiac failure (placebo, 3%; filgrastim, 0%), and COPD (placebo, 2%; filgrastim, 0%).
Sixty-seven patients (28%) in the placebo group and 59 patients (25%) in the filgrastim-treated group had severe adverse events, including ARDS (placebo, 16; filgrastim, 23), pneumonia (placebo, 13; filgrastim, 16), septic shock (placebo, 12; filgrastim, 9), and respiratory insufficiency (placebo, 9; filgrastim, 5).
Among those patients evaluable for safety, 46 deaths were observed through day 29: 27 (11%) occurred in placebo patients and 19 (8%) in the filgrastim-treated patients. The primary causes of death were pneumonia/sepsis (placebo, 8; filgrastim, 6), pneumonia (placebo 6; filgrastim, 10), cardiac failure (placebo, 5; filgrastim, 1), and COPD (placebo, 4; filgrastim, 0).
Analysis of safety data (475 patients evaluable for safety) showed that filgrastim was safe and well tolerated when administered to 235 patients with multilobar pneumonia. In the 29-day treatment period, the incidence of severe adverse events was similar across treatment groups.
Discussion
Endogenous granulocyte colony-stimulating factor concentrations are increased in a variety of infectious disease states [5] , which suggests that this growth factor has an important role in these settings. More than 50 studies evaluating the efficacy of filgrastim in animal models of infection have shown that filgrastim can augment host responses to a variety of infectious organisms (for review, see [6] ). Data from several studies indicate that filgrastim is safe and well tolerated in patients with nonneutropenic infections, such as diabetic foot infection [7] [8] [9] .
In the current trial, filgrastim appeared to be safe and well tolerated when administered to 235 patients with multilobar pneumonia. Filgrastim had no clinically significant effects on laboratory values other than WBC count. Filgrastim increased WBC count to a median peak of /L from a median 13.3 ϫ 10 filgrastim demonstrating an increase in WBC count.
The placebo and filgrastim-treated groups were not statisti-cally significantly different with respect to the primary end point, the incidence of treatment failure, although there were 3% more deaths in the placebo group, compared with the filgrastim-treated group. On examination of the deaths in the placebo and filgrastim groups, it was found that patients with positive baseline blood cultures for S. pneumoniae who received filgrastim showed a reduced mortality, compared with patients who received placebo. The historically reported mortality from patients with severe CAP is 20%-53% [10, 11] . A previous study [1] and a subsequent one (R. K. Root, T. J. Marrie, R. F. Lodato, et al., unpublished data) failed to show any benefit in patients with bacteremic pneumococcal pneumonia. Animal studies, however, suggest that filgrastim may accelerate clearance of pathogens from the lungs, either by increasing the number of neutrophils or by enhancing the function of the neutrophils [6] .
